Vibha Jawa

Vibha Jawa

Auto-generated profile, based on publicly available information

Vibha Jawa

EpiVax, Inc, Providence, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 July 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
IGIndiwari Gopallawa
Indiwari Gopallawa
CGCharu Gupta
Charu Gupta
RJRayan Jawa
Rayan Jawa
ACArya Cyril
Arya Cyril
VJVibha Jawa
Vibha Jawa
Vikramsingh GujarVikramsingh Gujar
Vikramsingh Gujar

23 September 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
JCJesper Kammersgaard Christensen
Jesper Kammersgaard Christensen
NCNicholas Colletti
Nicholas Colletti
SHShirin Hooshfar
Shirin Hooshfar
RJRongrong(Rosa) Jiang
Rongrong(Rosa) Jiang
CKCarol Kuo
Carol Kuo
VJVibha Jawa
Vibha Jawa
RNA-based therapies, particularly small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), represent a promising modality class with the potential to target previously “undruggable” proteins, and with potential for precision medicine approach. The successful development of these therapeutics relies on a comprehensive understanding of several key factors, including bioconjugation, bioanalytical techniques, biotransformation, tissue distribution, computational modeling and simulation, and clinical pharmacology. Bioconjugation strategies are essential for enhancing metabolic stability, facilitating cellular uptake, and targeting specific tissues, thereby improving efficacy and minimizing dosing. Tailored bioanalytical methods are crucial for assessing pharmacokinetics (PK) and pharmacodynamics, with particular emphasis on tissue PK in cases where plasma PK does not reflect therapeutic activity. Biotransformation and tissue distribution studies are essential, although a less comprehensive package may be adequate for well-established chemistry. Given the unique properties of oligonucleotides, computational modeling plays a critical role in predicting drug behavior in target tissues, supporting dose optimization. Clinical pharmacology for oligonucleotides is less complex than for small molecules, as they are less likely to interact with common drug metabolizing enzymes or transporter proteins. This white paper, developed by the Innovation and Quality (IQ) Consortium Nucleic Acids Working Group, consolidates industry insights and recommendations to inform best practices and regulatory guidelines, ensuring the safe and efficient development of siRNA and ASO therapies.

3 February 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
VJVibha Jawa
Vibha Jawa
JMJad Maamary
Jad Maamary
MSMichael Swanson
Michael Swanson
SZShuli Zhang
Shuli Zhang
DMDiana Montgomery
Diana Montgomery

22 July 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PGParidhi Gupta
Paridhi Gupta
JRJosiah T. Ryman
Josiah T. Ryman
VJVibha Jawa
Vibha Jawa
BMBernd Meibohm
Bernd Meibohm
Therapeutic protein administration in both preclinical and clinical studies can result in the formation of anti‐drug antibodies against the therapeutic protein. Anti‐drug antibody formation may alter the pharmacokinetics of the therapeutic protein, reduce its plasma concentrations, increase exposure variability, and may lead to a loss of efficacy and adverse events. In an effort to quantitatively understand the effect of anti‐drug antibodies on the concentration‐time profile of a therapeutic protein, as well as develop effective strategies to mitigate its impact in the preclinical and clinical development of therapeutic proteins, mathematical models have been developed to characterize the therapeutic protein pharmacokinetics and its modulation by anti‐drug antibodies in vivo. Here, we review several different mechanism‐based modeling frameworks, summarize their approaches to predict immunogenicity effects, and explore the merits and limitations of each model.

18 May 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JMJohanna Mora
Johanna Mora
DFDaron Forman
Daron Forman
JHJennifer Hu
Jennifer Hu
AIAkshata Ijantkar
Akshata Ijantkar
JGJochem Gokemeijer
Jochem Gokemeijer
CAChloé Ackaert
Chloé Ackaert